ReviewCureus2025
CardioMEMS Heart Failure System: An Up-to-Date Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Revolutionizing Heart Failure Management With Artificial Intelligence: A Narrative Review of Diagnostic, Prognostic, and Therapeutic Innovations.Health science reports · 2026Article
- AI-Enabled Sensor Technologies for Remote Arrhythmic Monitoring in High-Risk Cardiomyopathy Genotypes.Sensors (Basel, Switzerland) · 2026Review
- Remote Hemodynamic Monitoring in Heart Failure Management: A Comprehensive Review of Recent Advances and Clinical Challenges.Biomedicines · 2025Review
- The Impact of Remote Patient Monitoring on Clinical Outcomes in Heart Failure Patients: A Meta-Analysis.Cureus · 2025Review
- Technological Advances and Medical Applications of Implantable Electronic Devices: From the Heart, Brain, and Skin to Gastrointestinal Organs.Biosensors · 2025Review
- Advancements in Wearable and Implantable BioMEMS Devices: Transforming Healthcare Through Technology.Micromachines · 2025Review
- Implantable Biosensors for Vascular Diseases: Directions for the Next Generation of Active Diagnostic and Therapeutic Medical Device Technologies.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) continues to represent a significant public health concern. While patients with HF with reduced ejection fraction (HFrEF) face a high risk of arrhythmias, both patients with HFrEF and HF with preserved ejection fraction (HFpEF) experience fluid overload, leading to repeated hospitalizations. Traditional monitoring methods have limited ability to manage HF exacerbations preemptively. However, the CardioMEMS™ (Abbott Laboratories, Chicago, IL) HF system, an implantable microelectromechanical sensor, has emerged as an innovative solution, enabling real-time remote monitoring of pulmonary artery pressures (PAPs). CardioMEMS has significantly reduced HF-related hospitalizations and improved patient quality of life (QOL) by facilitating early intervention before clinical symptoms. This article explores the technical specifications, clinical efficacy, integration into clinical practice, and economic impact of the CardioMEMS system. Furthermore, we discuss the challenges and limitations associated with its widespread adoption and propose considerations for future research to enhance its cost-effectiveness and accessibility in diverse healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.